SGRY

Surgery Partners, Inc.
CAPPED RATING

Surgery Partners, Inc., through its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company operates through two segments, Surgical Facility Services and Ancillary Services. Its surgical facilities comprise ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including gastroenterology, general surgery, ophthalmology, orthopedics, and pain management. The company's surgical hospitals also provide ancillary services, such as diagnostic imaging, pharmacy, laboratory, obstetrics, oncology, physical therapy, and wound care; and ancillary services, which consist of multi-specialty physician practices, urgent care facilities, and anesthesia services. As of December 31, 2021, it owned or operated a portfolio of 126 surgical facilities, including 108 ambulatory surgical centers and 18 surgical hospitals in 31 states. Surgery Partners, Inc. was founded in 2004 and is headquartered in Brentwood, Tennessee.

Surgery Partners, Inc. (SGRY) is rated D+ (1.8/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Momentum (B); its weakest is Revisions (F). The rating has held at D+ for 2 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
1.8 / 5.0
D+
Value
C-
Factor Score 2.1 / 5.0
Growth
D
Factor Score 1.3 / 5.0
Profitability
C
Factor Score 2.3 / 5.0
Momentum
B
Factor Score 3.5 / 5.0
Revisions
F
Factor Score 0.0 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 134.7
EV / EBITDA 12.9
Rev Growth YoY -0.8%
Gross Margin 22.2%
Price Return 3M 87.7%
Price Return 12M 69.9%
Catalyst Signal 0.00
Market Cap $3.5B
TTM Revenue $3.4B
Price / Sales 1.0
ROE 2.1%

Historical Factor Score Progression

Held D+ for 2 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-14 C- (2.1) D (1.3) C (2.3) B (3.5) F (0.0) D+ (1.8)
2026-11-07 C- (2.1) D (1.4) C (2.4) B- (3.0) F (0.0) D+ (1.8)
2026-10-31 C- (2.1) D (1.4) C (2.3) B- (2.9) F (0.0) D+ (1.7)
2026-10-24 C+ (2.7) D+ (1.5) C (2.3) C+ (2.6) C+ (2.6) C (2.3)
2026-10-17 C+ (2.7) D+ (1.5) C (2.3) C (2.3) C+ (2.6) C (2.3)
Page 1 of 4